From: Hugin
[medialists@huginonline.com]
Sent: 06 March 2008 09:03
To:
Hugin media lists
Subject: Vitamin K Status in Children Improves Bone
Health in New Study

Published: 10:02 06.03.2008 GMT+1 /HUGIN /Source: NattoPharma /OSE:
NATTO /ISIN: NO0010289200
Vitamin K Status
in Children Improves Bone Health in New Study
A better vitamin K status was associated with more pronounced
increase in bone mass in healthy children - yet western populations are likely
vitamin K deficient
March
6, 2008 - Lysaker,
Norway
NattoPharma, Norway,
today note the publication of a new study demonstrating vitamin K's role in
promoting healthy bones in children. Published online at the British Journal of
Nutrition link, the researchers followed 307 healthy children, with an average
age of 11.2 years, over a two year period and measured skeletal bone mineral
content. They found improved status of the K vitamins over the two year period
resulted in better mineral content and improved bone mass of the whole body.
According to the lead
author, Marieke Summeren, Ph.D., "As children grow the increase in bone mass may
fail to keep up with the increase in height, or length of the bone, and as a
consequence, this imbalance may result in fracture." She continued, "But the
main threat of a long-term shortage of K vitamins is that peak bone mass may be
compromised, and as we age and begin to lose bone density, the risk of fracture
in later life is
increased."
Study author
Leon J. Schurgers,Ph.D.commented, "Numerous population studies and
interventional trials have established the consumption of K vitamins to bone
strength, structure and the reduction of the risk of fracture. This is due to
the need to activate the vitamin K-dependent protein osteocalcin, which is
essential for the body to utilize calcium in a healthy bone tissue.
Unfortunately, most people, including children, are likely deficient in the K
vitamins related to the need for bone health."
This is among the
first studies linking K vitamins to bone health in children. Vitamin K status
was evaluated by measured by the amount of active osteocalcin to inactive
osteocalcin. Without adequate vitamin K, the osteocalcin remains inactive, and
thus not effective. Previous research has evaluated vitamin K status in children
and found that they have inadequate K vitamins consumption to fully activate
osteocalcin.
"There are two
types of vitamin K from dietary sources. Vitamin K1 is found in leafy green
vegetables, and Vitamin K2, also called menaquinones, are predominately found in
fermented cheeses, curd, and the fermented soy called natto," stated Schurgers.
"Vitamin K1 is mostly used by the liver where it is involved in the synthesis of
certain blood clotting factors. Vitamin K2 is also equally active outside the
liver, in tissues including bone. Thus it is important to have good sources of
both types of vitamin
K!"
The recommended intakes
of vitamin K today are based solely on coagulation. However, K vitamins are also
necessary for the activation of osteocalcin, a protein necessary to transport
calcium from the blood to form healthy bone matrix. Also, K vitamins are needed
to activate matrix GLA protein (MGP), the most potent inhibitor of vascular
calcification known. In essence, K vitamins are necessary to keep calcium in
your bones and out of your arteries.
About Vitamin K2
The role of newly recognized vitamin K2 has for the
past decade been linked to two of the most important health issues, osteoporosis
and cardiovascular disease. This link specifically centers on calcium
utilization- implying that there is concurrent arterial calcification and
osteoporosis when metabolism of calcium is inadequate. K vitamins are essential
to activate proteins involved in calcium metabolism.
Numerous population
studies and interventional trials have established the consumption of vitamins K
and K2 to bone strength, structure and the reduction of the risk of fracture.
More recently, and specifically to vitamin K2, a significant role in
cardiovascular health has been established.
A study
published in the Journal of Nutrition called the "Rotterdam Study" in 2004,
followed over 4,800 people for a ten year period. The study found increased
intake of specifically vitamin K2 from dietary sources significantly reduced the
incidence of arterial calcification and the risk of CHD mortality by 50% as
compared to low dietary vitamin K2 intake. In this study, vitamin K1 had no
effect at all.
#
# #
For more information,
contact Morten Sundstø at +47 950 61 860
NattoPharma ASA offers
a natural vitamin K2 under the trade name MenaQ7.
About MenaQ7(TM)
MenaQ7 provides Natural Vitamin K2 as an
extract of natto, a fermented soy food from Japan. Natto is particularly rich in
the highly bio-available form of vitamin K2 called menaquinone-7 (MK-7). MenaQ7
provides the only commercially available Natural Vitamin K2 with guaranteed
actives and stability, clinical substantiation and international patents awarded
and pending.
For more
information on the health benefits of MenaQ7, please visit www.menaq7.com
About NattoPharma
NattoPharma, Norway, is a
publically-traded company and the exclusive international supplier and brand
owner of MenaQ7 natural Vitamin K2. NattoPharma has entered into a multi-year
research and development program to substantiate and discover the health
benefits of natural vitamin K2 for applications in the exciting marketplace for
functional food and health food supplements. www.nattopharma.com
This content was distributed through
- connecting communication professionals with their
target audience. Visit us
here. Unsubscribe |